STOCK TITAN

Masimo Corp - MASI STOCK NEWS

Welcome to our dedicated news page for Masimo (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Masimo's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Masimo's position in the market.

Rhea-AI Summary
Masimo (NASDAQ: MASI) and UCHealth announced a strategic collaboration to enhance patient care through virtual care and telehealth. The partnership aims to improve patient outcomes, reduce care costs, and transform care delivery models. Joe Kiani, Masimo's CEO, and Dr. Richard Zane from UCHealth expressed excitement about combining technological and clinical expertise to innovate healthcare solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
partnership
-
Rhea-AI Summary
Masimo (MASI) introduces MightySat® Medical, the first FDA-cleared fingertip pulse oximeter for OTC use without a prescription. Powered by Masimo SET® pulse oximetry, it offers accurate readings for medical purposes. The device is now available for purchase on masimo.com and will soon be in retail stores nationwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
Rhea-AI Summary
Masimo (NASDAQ: MASI) announces the findings of a study that evaluated the impact of low perfusion on the performance of Masimo SET® pulse oximetry across a variety of skin pigmentations. The study demonstrated that Masimo RD SET® sensors accurately measured oxygen saturation for both Black and White subjects, adding to the body of evidence that Masimo SET® pulse oximetry delivers accurate values across the skin tone range, with no clinically significant difference in accuracy or bias, even in challenging conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
Rhea-AI Summary
Masimo (NASDAQ: MASI) celebrates the Federal Circuit's decision to lift the temporary stay on the import ban of certain Apple Watch models, reinstating the U.S. International Trade Commission's import ban and cease and desist order on Apple watches infringing Masimo's patented pulse oximetry technology. The CEO, Joe Kiani, emphasizes the importance of upholding American inventors' rights and highlights the superiority of Masimo's pulse oximetry technology over Apple Watch's. Masimo's FDA-cleared W1® health watch is positioned as a more reliable alternative, with proven benefits in medical settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
-
Rhea-AI Summary
Masimo (NASDAQ: MASI) has appointed Bob Chapek, former CEO of The Walt Disney Company, to its Board of Directors. Chapek's successful leadership at Disney during the global COVID-19 pandemic, strategic realignment of media and entertainment divisions, and expansion of streaming services make him a valuable addition to Masimo's growth plans. Masimo's Chairman and CEO, Joe Kiani, expressed excitement about Chapek's role in advancing the company's hospital to home strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
management
-
Rhea-AI Summary
Masimo Corporation (MASI) announced preliminary financial results for Q4 and full-year 2023, with consolidated revenue of $541-551 million for Q4 and $2,041-2,051 million for full-year 2023. Full-year 2024 guidance includes consolidated revenue of $2,045-2,165 million, with updated non-GAAP earnings per diluted share of $3.44-3.60.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.55%
Tags
earnings
Rhea-AI Summary
Masimo (NASDAQ: MASI) receives FDA clearance for Stork™, a baby monitoring system for prescription use with babies 0-18 months. Stork provides continuous monitoring of oxygen saturation, pulse rate, and skin temperature, with alarms, for sick and healthy babies at home. It leverages the same Masimo sensor technology used in hospitals and is now available for prescription use as a medical device for healthy or sick babies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
clinical trial
-
Rhea-AI Summary
Masimo (NASDAQ: MASI) announces findings from a study on the association of Masimo ORi™ and arterial partial pressure of oxygen in patients undergoing non-cardiac thoracic surgery during one-lung ventilation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Summary
Masimo (MASI) to participate in Piper Sandler 35th Annual Healthcare Conference on November 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
Rhea-AI Summary
Masimo (NASDAQ: MASI) Receives FDA Clearance for W1 Medical Watch for OTC and Rx Use
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Masimo Corp

Nasdaq:MASI

MASI Rankings

MASI Stock Data

6.91B
44.01M
7.7%
96.89%
9.35%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
US
Irvine

About MASI

masimo (nasdaq: masi) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. our work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life for more than 27 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. the result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making. masimo is for‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see. we're looking for people who can, do, and will make a difference. we think you'll like what you see.